Gain Therapeutics Announces Proposed Public Offering to Drive Growth and Expand Operations
BETHESDA, Md. June 13, 2024 - Gain Therapeutics, Inc.(Nasdaq: GANX), a leading biotechnology company specializing in the development of novel therapeutics for neurodegenerative diseases, announced today its intention to conduct an underwritten public offering of its common stock (or pre-funded warrants in lieu thereof) subject to market conditions.The company aims to raise capital to support its growth strategy, including expanding its research and development efforts and advancing its pipeline of innovative drug candidates.
The proposed public offering will provide Gain Therapeutics with the opportunity to offer and sell shares of its common stock or pre-funded warrants to interested investors.The final terms and pricing of the offering will depend on market conditions and other factors and will be determined at the time of pricing.Gain Therapeutics expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock and pre-funded warrants offered in the offering.
By conducting a public offering, Gain Therapeutics aims to further strengthen its financial position, enabling it to accelerate the development of its potential disease-modifying therapies.This capital infusion will allow the company to continue its ground-breaking research into novel targets and identify new lead compounds utilizing its unique proprietary platform, Site-Directed Enzyme Enhancement Therapy (SEE-Txâ„¢).
Investors and analysts have been closely following the progress of Gain Therapeutics as it develops therapies for a range of neurodegenerative disorders, including Parkinson’s disease and Alzheimer’s disease.With an increasing aging population worldwide, the need for effective treatments for these conditions has never been more urgent.
At the time of the announcement, Gain Therapeutics Inc.had 17.978951 million shares outstanding, with the current stock price standing at $2.11.This information provides potential investors with valuable insights into the company’s current market value and growth potential.
The proceeds from the public offering will be utilized to advance Gain Therapeutics’ robust pipeline, which includes promising drug candidates targeting various neurodegenerative diseases.The company’s lead candidate, GT-0198, has shown promising preclinical results and has significant potential to address the unmet medical needs of patients suffering from neurodegenerative diseases.
Several factors contribute to the optimism surrounding Gain Therapeutics’ potential for long-term success.The company’s unique approach to drug discovery, centered around its proprietary SEE-Txâ„¢ platform, has garnered attention from the scientific community.By leveraging advanced computational algorithms and structural biology, Gain Therapeutics can identify novel drug targets and design small molecules to enhance the functions of specific enzymes.
Moreover, Gain Therapeutics has tapped into a large market opportunity, with the global neurodegenerative disease therapeutic market estimated to reach $62.3 billion by 2026.With the increasing prevalence of these diseases and the limited treatment options currently available, the potential economic and societal impact of Gain Therapeutics’ drug candidates cannot be overstated.
In summary, Gain Therapeutics’ proposed public offering reflects the company’s commitment to advancing the development of innovative therapeutics for neurodegenerative diseases.The capital raised through this offering will provide the necessary resources to expand research and development efforts, further its lead candidate’s clinical development, and potentially unlock groundbreaking treatments for patients in need.
Comments